Thyroid Clinical Trials
Here are the 6 most popular medical studies for thyroid
Calcium Carbonate and Calcitriol Treatments for Hypoparathyroidism
This trial will compare two protocols for treating post-thyroidectomy hypoparathyroidism. One protocol uses PTH to guide calcium repletion, while the other uses empiric repletion. The goal is to see which protocol results in a better quality of life for patients.
Phosphodiesterase Inhibitor
Theophylline for Pseudohypoparathyroidism in Children
This trial will test if theophylline can help with weight loss, growth plate closure, and hormone resistance in children with pseudohypoparathyroidism, a disorder with limited treatment options.
Hormone Therapy
TransCon PTH for Hypoparathyroidism
This trial is testing a new medication, TransCon PTH, to see if it is effective and safe for people with a certain medical condition. The trial will last for four weeks, during which participants will be given either TransCon PTH or a placebo. After the four weeks, all participants will receive TransCon PTH.
PD-L1 Inhibitor
RAI Plus Immunotherapy for Thyroid Cancer
This trial is testing a new drug, durvalumab, to see if it can help treat thyroid cancer. Durvalumab blocks a protein that can be present on tumor and normal cells, which may help the immune system fight the cancer.
Popular filter options for thyroid trials
Thyroid Carcinoma Clinical Trials
View 47 Thyroid Carcinoma medical studies.
Kinase Inhibitor
Dabrafenib + Trametinib for Differentiated Thyroid Cancer
This trial is testing whether the combination of dabrafenib and trametinib is more effective than placebo for treating patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
Monoclonal Antibodies
Pembrolizumab + Dabrafenib + Trametinib for Anaplastic Thyroid Cancer
This trial is testing a combo of 3 drugs to treat patients with a specific mutation in their cancer cells. The drugs work by either stopping cell growth or by helping the body's immune system attack the cancer.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Anaplastic Thyroid Cancer
This trial is studying how well lenvatinib and pembrolizumab work together to treat patients with anaplastic thyroid cancer that cannot be removed by surgery or has spread to other parts of the body.
Radiopharmaceutical Therapy
CXRPT for Thyroid Cancer
This trial is testing a new way to treat thyroid cancer by combining two types of radiation. The goal is to see if it's safe and effective, and if it can deliver a high enough dose of radiation to the tumor.
Thyroid Cancer Clinical Trials
View 46 Thyroid Cancer medical studies.
Kinase Inhibitor
Dabrafenib + Trametinib for Differentiated Thyroid Cancer
This trial is testing whether the combination of dabrafenib and trametinib is more effective than placebo for treating patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Anaplastic Thyroid Cancer
This trial is studying how well lenvatinib and pembrolizumab work together to treat patients with anaplastic thyroid cancer that cannot be removed by surgery or has spread to other parts of the body.
Radiopharmaceutical Therapy
CXRPT for Thyroid Cancer
This trial is testing a new way to treat thyroid cancer by combining two types of radiation. The goal is to see if it's safe and effective, and if it can deliver a high enough dose of radiation to the tumor.
BRAF Positive Clinical Trials
View 11 BRAF positive medical studies.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Anaplastic Thyroid Cancer
This trial is studying how well lenvatinib and pembrolizumab work together to treat patients with anaplastic thyroid cancer that cannot be removed by surgery or has spread to other parts of the body.
Tyrosine Kinase Inhibitor
Selpercatinib + Cabozantinib + Vandetanib for RET-Mutant Medullary Thyroid Cancer
This trial is testing a new drug to see if it's more effective and safe than the current standard treatment for people with a certain type of thyroid cancer.
Kinase Inhibitor
Dabrafenib + Trametinib + IMRT for Anaplastic Thyroid Cancer
This trial is testing whether combining dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) is more effective at treating patients with BRAF mutated anaplastic thyroid cancer than just using IMRT alone.
RET Positive Clinical Trials
View 6 RET positive medical studies.
Tyrosine Kinase Inhibitor
Pralsetinib for Medullary Thyroid Cancer
This trial will compare the effectiveness of a new drug, pralsetinib, to the standard of care (SOC) treatment for people with a specific type of thyroid cancer. Participants will be randomly assigned to either the new drug or the SOC treatment. If their disease progresses while taking the SOC treatment, they will be offered the new drug.
Tyrosine Kinase Inhibitor
Selpercatinib + Cabozantinib + Vandetanib for RET-Mutant Medullary Thyroid Cancer
This trial is testing a new drug to see if it's more effective and safe than the current standard treatment for people with a certain type of thyroid cancer.
Tyrosine Kinase Inhibitor
Pralsetinib for Thyroid Cancer and Non-Small Cell Lung Cancer
This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
Kinase Inhibitor
Sorafenib Tosylate for Medullary Thyroid Cancer
This trial looks at how well a drug called sorafenib tosylate works in treating patients with thyroid cancer that has spread or returned. The drug may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Phase 3 Thyroid Clinical Trials
View 97 phase 3 thyroid medical studies.
Monoclonal Antibodies
VRDN-001 for Thyroid Eye Disease
This trial is testing a new drug, VRDN-001, to see if it's safe and effective in treating thyroid eye disease. The drug works by inhibiting a cell surface receptor called IGF-1R. If the drug is effective, it could help reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease.
Kinase Inhibitor
Dabrafenib + Trametinib for Differentiated Thyroid Cancer
This trial is testing whether the combination of dabrafenib and trametinib is more effective than placebo for treating patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
Tyrosine Kinase Inhibitor
Pralsetinib for Medullary Thyroid Cancer
This trial will compare the effectiveness of a new drug, pralsetinib, to the standard of care (SOC) treatment for people with a specific type of thyroid cancer. Participants will be randomly assigned to either the new drug or the SOC treatment. If their disease progresses while taking the SOC treatment, they will be offered the new drug.
Tyrosine Kinase Inhibitor
Selpercatinib + Cabozantinib + Vandetanib for RET-Mutant Medullary Thyroid Cancer
This trial is testing a new drug to see if it's more effective and safe than the current standard treatment for people with a certain type of thyroid cancer.
Thyroid Clinical Trials With No Placebo
View 97 thyroid medical studies that do not have a placebo group.
Monoclonal Antibodies
Pembrolizumab + Dabrafenib + Trametinib for Anaplastic Thyroid Cancer
This trial is testing a combo of 3 drugs to treat patients with a specific mutation in their cancer cells. The drugs work by either stopping cell growth or by helping the body's immune system attack the cancer.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Anaplastic Thyroid Cancer
This trial is studying how well lenvatinib and pembrolizumab work together to treat patients with anaplastic thyroid cancer that cannot be removed by surgery or has spread to other parts of the body.
View More Thyroid Trials
See another 69 many medical studies focused on thyroid.
Frequently Asked Questions
Introduction to thyroid
What are the top hospitals conducting thyroid research?
When it comes to cutting-edge clinical trials focused on thyroid conditions, several top hospitals are making significant strides. One of these institutions is the Memorial Sloan Kettering Cancer Center located in New Yorkn thyroid conditions, several top hospitals are making significant strides. One of these institutions is the Memorial Sloan Kettering Cancer Center located in New York City. With an impressive 14 active trials currently underway, this center is dedicated to advancing research and treatment options for patients with thyroid-related issues. Similarly, the M D Anderson Cancer Center in Houston stands out with 11 ongoing clinical trials specifically targeting thyroid disorders. Their commitment to exploring innovative approaches brings hope to those affected by thyroid conditions. Another prominent hospital contributing valuable insights is the Mayo Clinic in Rochester, which has a commendable eight active thyroid trials happening at present. This institution's dedication to improving patient care through scientific investigation makes them a leader in the field of thyrology.
The Ohio State University Comprehensive Cancer Center based in Columbus also plays a critical role in advancing our understanding of thyroid diseases through their five current clinical trials focusing on this area. By actively engaging in research and seeking breakthroughs, they aim to enhance treatment outcomes for individuals diagnosed with such conditions.
Even smaller-scale facilities like Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) located in Basking Ridge participate actively as well; despite having only four ongoing thyroid trials presently being conducted there, their contribution remains invaluable.
These esteemed hospitals collectively exemplify a commitment towards unravelling mysteries surrounding various aspects of thyrological complications that millions worldwide face every day.. Through collaborative efforts and unwavering determination, they strive toward discovering effective therapies that will ultimately improve lives and offer brighter futures for those impacted by these conditions
Which are the best cities for thyroid clinical trials?
When it comes to thyroid clinical trials, several cities in the United States lead the way in research and development. New York City boasts 27 active trials, exploring treatments like TransCon PTH, PET/CT Scan, and Vemurafenib. Houston, Texas follows closely behind with 22 ongoing studies focused on Pembrolizumab, pralsetinib (BLU-667), and Double-Blind Phase PLS240 among others. Boston, Massachusetts. New Yo to thyroid clinical trials, several cities in the United States lead the way in research and development. New York City boasts 27 active trials, exploring treatments like TransCon PTH, PET/CT Scan, and Vemurafenib. Houston, Texas follows closely behind with 22 ongoing studies focused on Pembrolizumab, pralsetinib (BLU-667), and Double-Blind Phase PLS240 among others. Boston, Massachusetts is also a hub for thyroid clinical trials with 19 active studies examining pralsetinib (BLU-667), Paricalcitol, Tirosint®-SOL, and more. Philadelphia and Rochester are additional key locations with significant ongoing research initiatives. These cities offer individuals dealing with thyroid conditions access to cutting-edge clinical trials that pave the way for advancements in treatment options and improve patient outcomes.
Which are the top treatments for thyroid being explored in clinical trials?
Clinical trials for thyroid treatments are underway, with several promising options currently being explored. Among the top contenders are:
- Lenvatinib: An active participant in multiple clinical trials, lenvatinib has shown potential as an effective treatment for thyroid conditions.
- Sorafenib: Another notable candidate, sorafenib is currently being investigated in various clinical studies focused on identifying its efficacy in treating thyroid-related ailments.
As researchers delve deeper into these clinical trials, they aim to uncover new and improved treatment options that can bring hope to individuals battling thyroid issues.
What are the most recent clinical trials for thyroid?
Recent clinical trials have explored new possibilities for the treatment of thyroid conditions. Among these studies is a Phase 2 trial investigating radioiodine-refractory, recurrent and/or metastatic differentiated thyroid cancerf thyroid conditions. Among these studies is a Phase 2 trial investigating radioiodine-refractory, recurrent and/or metastatic differentiated thyroid cancer (DTC). Additionally, a Phase 3 trial is examining the efficacy of eneboparatide in patients with thyroid disorders. Another Phase 3 trial, known as Double-Blind Phase PLS240, focuses on evaluating a potential therapeutic option for individuals affected by thyroid-related issues. These ongoing trials offer hope for improved management and outcomes in patients with thyroid conditions.
What thyroid clinical trials were recently completed?
Recently, there have been several notable clinical trials focused on thyroid conditions that have reached completion. These trials aim to enhance our understanding and treatment options for thyroid-related disorders. One recent trial in particular investigated the potential benefits of a novel medication for treating hyperthyroidism. Another study examined the effectiveness of a targeted therapy for advanced thyroid cancern thyroid conditions that have reached completion. These trials aim to enhance our understanding and treatment options for thyroid-related disorders. One recent trial in particular investigated the potential benefits of a novel medication for treating hyperthyroidism. Another study examined the effectiveness of a targeted therapy for advanced thyroid cancer patients who had not responded well to standard treatments. These advancements signify important progress in the field and offer hope for individuals affected by thyroid disorders.